Medicinal cannabis and cosmetics firm MGC Pharmaceuticals has won approval from the US regulator to sell its cannabis-based anti-ageing cosmetics in America.
MGC says approval from the US Food and Drug Administration (FDA) marks the company's entry into the $US11 billion ($A15.32 billion) US skin care market.
The company also said it had made its first US sale, through a new distribution deal with California's C&M CBD Holding for cannabis-based cosmetic products.
MGC is seeking other distribution partners in key US states.
The firm said FDA approval for the first 16 of its products means its cannabis-based cosmetics can be imported and sold throughout the USA, even in states where medicinal cannabis is not yet legal.
The news boosted MGC's shares, which gained 7.7 per cent to 5.6 cents.
The European Commission recently granted MGC approval to sell its cannabis-based cosmetics throughout the European Union.
MGC has already made its first sale in Europe and has an exclusive distribution agreement with Czech Medical Herbs.
MGC is also seeking approval for its cosmetics in Australia and Canada.
Managing director Nativ Segev MGC's next step was to advance the use of medicinal cannabis in the pharmaceuticals sector.
